CriticalSSRI×Antidepressants. Other antidepressants of herbal origin
Updated · Methodology
Mechanism
St John's wort extract inhibits the synaptosomal reuptake of serotonin, noradrenaline and dopamine (St John's wort summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 5.1), and fluvoxamine is a selective serotonin reuptake inhibitor (SSRI). The interaction table of the St John's wort SmPC lists increased serotonergic effects and a higher incidence of adverse reactions with SSRIs, including fluvoxamine (St John's wort SmPC, AEMPS, section 4.5). The fluvoxamine SmPC states that St John's wort preparations may increase the serotonergic effects of fluvoxamine, up to a potentially life-threatening condition (fluvoxamine SmPC, AEMPS, section 4.5). Hyperforin in St John's wort induces CYP3A4, CYP2C9 and CYP2C19 (St John's wort SmPC, AEMPS, section 5.2), while the main enzyme in fluvoxamine metabolism is CYP2D6 (fluvoxamine SmPC, AEMPS, section 5.2). The documents give no data on how St John's wort changes fluvoxamine levels.
Symptoms
The main risk is serotonin syndrome. The fluvoxamine summary of product characteristics (SmPC) describes hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuation of vital signs, and mental status changes including confusion, irritability and extreme agitation progressing to delirium and coma (fluvoxamine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.4). The fluvoxamine label of the US Food and Drug Administration (FDA) adds hallucinations, dizziness, sweating, flushing, tremor, hyperreflexia, incoordination, seizures, nausea, vomiting and diarrhoea (FDA fluvoxamine label, section 5.2).
Management
The Spanish St John's wort summary of product characteristics (SmPC) contraindicates the combination: St John's wort must not be used with antidepressants, especially selective serotonin reuptake inhibitors (SSRIs), and its interaction table names fluvoxamine (St John's wort SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, sections 4.3 and 4.5). The authorisation of this product has been suspended since 11 June 2026, and there is no other current Spanish St John's wort SmPC. The fluvoxamine SmPC has no contraindication but warns of a potentially life-threatening increase in serotonergic effects (fluvoxamine SmPC, AEMPS, section 4.5). If the two have nevertheless been taken together, monitor for signs of serotonin syndrome, particularly at the start of treatment and after dose increases (fluvoxamine label, US Food and Drug Administration, FDA, section 7). If serotonin syndrome develops, stop fluvoxamine and start symptomatic treatment (fluvoxamine SmPC, AEMPS, section 4.4). No document says how long to wait between stopping St John's wort and starting fluvoxamine. Increased enzyme activity returns to normal within 1 week of stopping St John's wort (St John's wort herbal monograph, European Medicines Agency, EMA, section 4.5).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica Dumirox 100 mg (fluvoxamina) (2025)– AEMPS CIMA, Dumirox 100 mg comprimidos recubiertos con película, nº registro 58212, revisión 06/2025, secciones 4.3, 4.5 y 5.2
- FDA: Fluvoxamine maleate tablets prescribing information (Apotex) (2026)– Apotex Corp. Fluvoxamine maleate tablets. Prescribing information, DailyMed setid 6eeb14df-6fcf-a737-5359-5744eb4accea, sections 4, 5.8, 5.10 and 7 (Luvox brand is no longer listed)
- AEMPS: Ficha técnica: Hipérico (Hypericum perforatum) (nº registro 79963), secciones 4.3 y 4.5 (2025)– AEMPS, CIMA, Hipérico Arkopharma cápsulas duras, nº registro 79963, documento 11/2025 (fecha de revisión del texto 09/2016), secciones 4.3, 4.4 y 4.5; autorización suspendida desde el 11.06.2026, única ficha técnica de hipérico no revocada en CIMA
- EMA: European Union herbal monograph on Hypericum perforatum L., herba – Revision 1 (EMA/HMPC/7695/2021) (2022)– EMA, Committee on Herbal Medicinal Products (HMPC), European Union herbal monograph on Hypericum perforatum L., herba, Final – Revision 1, EMA/HMPC/7695/2021, 23.11.2022 (publicada 22.02.2023), secciones 4.1, 4.3 y 4.5